Indivior Pharmaceuticals — Business Overview

What does Indivior do?

Indivior is a specialty pharmaceutical company laser-focused on treating opioid use disorder (OUD), a chronic brain disease marked by compulsive opioid use despite harmful consequences. It sells two core prescription medications in the U.S.: SUBLOCADE, a once-monthly injectable form of buprenorphine (a partial opioid agonist that reduces cravings and blocks the "high" from other opioids), and SUBOXONE Film, a dissolving strip placed under the tongue combining buprenorphine with naloxone. Outside the U.S., it also sells SUBUTEX Tablet (buprenorphine-only) in Australia, France, and Germany.

Indivior has recently sharpened its focus significantly. In 2025, it discontinued active marketing of OPVEE (an overdose-reversal nasal spray) and PERSERIS (a schizophrenia injection), and it pulled out of several international markets including the U.K., Ireland, Sweden, Israel, Finland, and Italy. The company now intends to sell products only in the U.S., Canada, Australia, France, and Germany.

How does Indivior make money?

Indivior sells branded prescription medicines to patients through a network of specialty pharmacies, wholesale distributors, hospitals, and addiction treatment centers. Its three largest wholesale customers — large U.S. pharmaceutical distributors — accounted for 51% of global net revenues in 2025, though their relative share is declining as SUBLOCADE grows through specialty pharmacy channels. Approximately 90% of U.S. payors cover its OUD products, and over 95% of SUBLOCADE patients enrolled in its co-pay assistance program pay $0 out of pocket, meaning Medicaid and commercial insurers are the primary payers.

SUBLOCADE is now the company's revenue engine, having overtaken SUBOXONE Film as the largest product by 2022. SUBLOCADE generated $856 million in net sales in 2025, while SUBOXONE Film contributed $346 million. Because Indivior's U.S. sales force no longer actively promotes SUBOXONE Film (a condition of its 2020 settlement with the Department of Justice), the film product is essentially in managed decline while SUBLOCADE is the sole focus of U.S. commercial activity.

What market does Indivior operate in?

Indivior operates in the U.S. market for medication-assisted treatment of opioid use disorder (OUD), a large and structurally undersupplied market. In 2024, approximately 4.8 million Americans had OUD, yet only 17% (around 818,000 people) received any medication for it. That 83% treatment gap represents both a public health crisis and a very large untapped commercial opportunity. Globally, the UN estimates 316 million people used drugs in 2023, with opioids responsible for roughly two-thirds of drug-related deaths.

The opioid crisis continues to drive demand for effective treatment, with synthetic opioids like fentanyl reshaping the urgency. About 47,000 opioid overdose deaths occurred in the U.S. in the 12 months ending August 2025, with fentanyl involved in 96% of those. Fentanyl's extreme potency (30–50 times stronger than heroin) has created new clinical arguments for high-dose, sustained buprenorphine delivery — directly supporting SUBLOCADE's product positioning.

Secular tailwinds include growing policy support, expanded insurance coverage, and destigmatization of medication-based treatment. The Affordable Care Act, Medicaid expansion, and advocacy by agencies like SAMHSA have widened access. Indivior also targets criminal justice systems (prisons, specialty courts) as a channel where OUD is prevalent and historically underserved.

Who are Indivior's main competitors?

SUBLOCADE's main branded competitor is BRIXADI (made by Camurus, marketed in the U.S. by Braeburn), the only other FDA-approved long-acting injectable buprenorphine. Outside the U.S., BRIXADI is sold as BUVIDAL and has first-mover advantage in most international markets, including Australia. In the U.S., SUBLOCADE was first to market and has treated over 475,000 patients since its 2018 launch, giving it an established clinical track record.

SUBOXONE Film faces significant generic competition in the U.S., with its category share down to an average of 14.2% in 2025. Four generic versions compete directly. Indivior no longer promotes the film in the U.S., making further share erosion likely. In contrast, the film retains patent protection in Europe and Canada until 2030, and faces no generics in Australia.

Indivior's key claimed advantages center on SUBLOCADE's once-monthly dosing, controlled delivery, and reduced diversion risk. Because SUBLOCADE is injected by a healthcare provider (not self-administered), the buprenorphine cannot be extracted and misused — a meaningful clinical and regulatory differentiator. Its patents protect the product in the U.S., Canada, and Australia, with several key U.S. patents extending as far as 2044.

Where does Indivior operate?

The U.S. is by far Indivior's dominant market, accounting for 85% of net revenues in both 2024 and 2025. U.S. operations cover sales, marketing, managed care, and medical affairs, with a field force of Clinical Specialists calling on organized health systems, addiction treatment centers, specialty pharmacies, and criminal justice institutions. The company is headquartered in North Chesterfield, Virginia.

Outside the U.S., Indivior has a shrinking but targeted international footprint. Canada and Australia are its two meaningful non-U.S. commercial markets, each with dedicated sales teams. France and Germany are retained for SUBUTEX Tablet sales, but without full local operations in Germany. In October 2025, Indivior exited the U.K., Ireland, Sweden, Israel, Finland, and Italy entirely.

Indivior manufactures its key active ingredient — buprenorphine — at its own Fine Chemical Plant in Hull, U.K., which it is retaining even after the broader U.K. exit. SUBLOCADE itself is manufactured under contract by Curia (a third-party contract manufacturer), and Indivior is simultaneously building out a backup manufacturing facility in Raleigh, North Carolina, to reduce supply concentration risk. SUBOXONE Film is made exclusively by Aquestive Therapeutics at two facilities in Portage, Indiana.